Universal Beteiligungs und Servicegesellschaft mbH Has $17.15 Million Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH trimmed its stake in Kenvue by 10.6% in Q4 and now holds 991,378 shares (about 0.05% of the company) valued at $17.15 million.
• Analysts collectively rate KVUE as a Hold with an average price target of $19.33 after recent downgrades and price-target cuts from firms including Barclays, Citi and Jefferies.
• Kenvue beat the latest quarter (EPS $0.27 vs. $0.22 consensus; revenue $3.78B) and pays a quarterly dividend yielding 4.7%, though the payout ratio is a high 107.79%, which could raise sustainability concerns.

Universal Beteiligungs und Servicegesellschaft mbH trimmed its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 10.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 991,378 shares of the company's stock after selling 116,980 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.05% of Kenvue worth $17,150,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. American Century Companies Inc. boosted its stake in shares of Kenvue by 22.4% during the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company's stock valued at $601,267,000 after purchasing an additional 6,781,640 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Kenvue by 13.5% during the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company's stock valued at $375,377,000 after purchasing an additional 2,747,952 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Kenvue by 101.3% during the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company's stock valued at $298,008,000 after purchasing an additional 9,240,434 shares in the last quarter. Amundi boosted its stake in shares of Kenvue by 21.6% during the third quarter. Amundi now owns 17,645,761 shares of the company's stock valued at $277,012,000 after purchasing an additional 3,135,871 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Kenvue by 2.3% during the third quarter. Legal & General Group Plc now owns 14,785,925 shares of the company's stock valued at $239,976,000 after purchasing an additional 332,870 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on KVUE. Weiss Ratings reissued a "hold (c-)" rating on shares of Kenvue in a research note on Wednesday, April 8th. Barclays lowered their price objective on Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 14th. Citigroup lowered their price objective on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research report on Wednesday, April 15th. Argus upgraded Kenvue to a "hold" rating in a research report on Friday, March 6th. Finally, Jefferies Financial Group downgraded Kenvue from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company's stock. According to data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average price target of $19.33.

Kenvue Price Performance

Shares of KVUE opened at $17.49 on Friday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The company has a market capitalization of $33.57 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 3.97 and a beta of 0.61. The business has a 50-day moving average of $17.82 and a 200-day moving average of $17.15.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.05. The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm's revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.26 earnings per share. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.1 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date was Wednesday, February 11th. Kenvue's payout ratio is presently 107.79%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.